



Published in final edited form as:

Nat Commun. ; 6: 7864. doi:10.1038/ncomms8864.

Redefining the concept of protease-activated receptors: cathepsin S evokes itch via activation of Mrgprs

Vemuri B. Reddy, PhD^{1,*}, Shuohao Sun^{2,*}, Ehsan Azimi, MD¹, Sarina B. Elmariah, MD, PhD¹, Xinzhong Dong, PhD², and Ethan A. Lerner, MD, PhD¹

¹Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Boston, MA 02129

²Department of Neuroscience, Johns Hopkins University, Baltimore, MD 21205

Abstract

Sensory neurons expressing Mas-related G protein coupled receptors (Mrgprs) mediate histamine-independent itch. We show that the cysteine protease cathepsin S activates MrgprC11 and evokes receptor-dependent scratching in mice. In contrast to its activation of conventional protease-activated receptors, cathepsin S mediated activation of MrgprC11 did not involve the generation of a tethered ligand. We demonstrate further that different cysteine proteases selectively activate specific mouse and human Mrgpr family members. This expansion of our understanding by which proteases interact with GPCRs redefines the concept of what constitutes a protease-activated receptor. The findings also implicate proteases as ligands to members of this orphan receptor family while providing new insights into how cysteine proteases contribute to itch.

Introduction

The sensation of itch is relayed from the skin to the brain via a complex but orchestrated series of signals. Itch is initiated when exogenous or endogenous pruritogens activate receptors or channels on the peripheral projections of primary sensory neurons the cell bodies of which reside in the dorsal root or trigeminal ganglia. Specific members of the family of Mas-related G-protein coupled receptors (Mrgprs) are expressed by a subset of nociceptive fibers¹. These receptors have been shown to bind select pruritogens in the periphery and mediate non-histaminergic itch^{2, 3}. For example, mouse MrgprA3 and human MRGPRX1 respond to chloroquine, an anti-malarial drug, and are responsible for relaying chloroquine-induced scratching in mice^{2, 4}. Mouse MrgprC11 and human MRGPRX1

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Address correspondence to: Ethan A. Lerner, MD, PhD, Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, 149 Thirteenth Street, Charlestown, MA 02129. Phone: 617.726.4439; Fax: 617.726.2120; elerner@mgh.harvard.edu.

*Contributed equally to the manuscript

Author contributions: VR and EAL conceived the overall design of the study. VR performed *in vitro* studies that were designed and analyzed with EAL. EA and SBE contributed to data interpretation. SD performed behavioural and DRG neuron studies that were designed, analyzed and interpreted with XD. All authors contributed to the writing and review of the manuscript.

Competing financial interests: none

respond to a different subset of pruritogens including bovine adrenal medulla peptide (BAM8-22). MrgprC11 is activated by SLIGRL and SLIGKV, the tethered ligand peptides of respective mouse and human protease-activated receptor-2 (PAR2) while MRGPRX2 is activated by SLIGKV^{2, 3, 5, 6}. Trypsin, a serine protease and conventional activator of PARs, does not activate Mrgprs^{3, 7}. In addition, β -alanine, a bodybuilding supplement known to cause itch upon ingestion, activates the MrgprD receptor expressed by nociceptive fibers⁸. In transgenic mice in which a cluster of *Mrgprs* has been ablated, cutaneous exposure to these pruritogens evokes significantly less scratching compared with wild-type (wt) controls. These findings underscore the importance of this family of receptors to peripheral detection of non-histaminergic itch stimuli and the subsequent activation of itch-specific neural pathways. While several exogenous compounds trigger Mrgpr activation, endogenous ligands or modulators of MrgprA3 and MrgprC11 receptors have yet to be identified.

Both serine and cysteine proteases have been implicated in triggering itch and inflammation in the skin. The plant cysteine protease mucunain, derived from the tropical bean plant commonly known as cowhage, and the human cysteine protease, cathepsin S (cat S) elicit itch in human volunteers^{9, 10}. We demonstrated previously that cat S, mucunain and other plant cysteine proteases including papain, bromelain, and ficin are capable of activating PAR2 and PAR4^{10, 11}. It has been presumed that cysteine protease-evoked itch was induced via PAR2 activation. The possibility that activation of receptors other than PARs could be responsible for this sensation has not been investigated. MrgprC11 is activated by SLIGRL, a synthetic peptide generated based on the tethered sequence of the PAR2 N-terminus following cleavage by serine proteases¹². This observation is surprising because Mrgprs are not members of the PAR family. MrgprC11 does not have either arginine or lysine residues in its N-terminal extracellular domain. This receptor would neither be cleaved nor in theory activated, by serine proteases including trypsins and kallikreins. In contrast, the MrgprC11 receptor N-terminus contains glycine and leucine residues, both cleavage targets for aspartyl and cysteine proteases¹³. Here, we formally investigated whether select cysteine proteases are capable of cleaving and activating MrgprC11 receptors *in vitro* and determined the significance of MrgprC11 signaling in mediating cat S-induced scratching *in vivo*.

The results demonstrate that cathepsin S provokes itching by cleavage of MrgprC11 at a specific site, resulting in activation of this receptor without generating either a tethered or diffusible ligand. Although cathepsin S can activate PAR2 receptors, such activation is not necessary for itching provoked by this protease. Hybrid receptors in which the N-terminus of MrgprC11 was replaced with the N-terminus from either the β 2AR or MC1R were also activated by cathepsin S. These findings highlight the possibility that cysteine proteases may exert effects on other 'non-PAR' GPCRs and further suggest that proteases are capable of modulating GPCRs by multiple mechanisms.

Results

Cysteine proteases cleave the N-terminus of MrgprC11

MrgprC11 plays a critical role in mediating pruriception from the periphery. These receptors are known to bind several well-recognized pruritogens, including peptides resulting from cleavage of PARs. Whether or not proteases have any direct effect on Mrgpr receptors was

not known. To address this possibility, we asked if cysteine proteases could cleave the extracellular N-terminal portion of MrgprC11. HeLa cells were transfected with a construct encoding MrgprC11 tagged with *Gaussia luciferase* at its N-terminus and then treated with cat S or papain. Receptor cleavage was assessed by measuring levels of luminescence in the supernatants (Fig. 1). Both papain and cat S induced cleavage of the MrgprC11 N-terminus as determined by luminescence (Fig. 1a). Incubation with E-64, an irreversible cysteine protease inhibitor, blocked protease-mediated cleavage of the N-termini. In separate studies, tagged MrgprC11-transfected cells were treated with cysteine proteases. Western blots of supernatants probed with an anti-*G. luciferase* antibody revealed a dense band at ~20 kDa in cells treated with cat S or papain, consistent with the mass expected of an N-terminal peptide tagged with *G. luciferase* (Fig. 1b). As expected, no bands were identified in controls in which transfected cells were not treated with protease. These results reveal that cysteine proteases cleave the N-terminal portion of MrgprC11.

Cysteine proteases activate MrgprC11 in vitro

We next asked whether cysteine proteases were capable of activating MrgprC11. This receptor signals via Gq, resulting in phospholipase C activation and, via second messenger recruitment, increased intracellular free Ca²⁺ and protein kinase C activation¹⁴. To assess receptor activation, we performed calcium imaging using the ratiometric calcium indicator Fura-2 in HeLa cells transfected with MrgprC11 following treatment with cat S or papain. Each protease elicited calcium responses (Fig. 2a), activating MrgprC11 in a concentration-dependent manner with an EC₅₀ of approximately 140 nM (Fig. 2b). Calcium responses were ablated when cells were treated with the protease inhibitor E-64 (Fig. 2a). In contrast to the robust responses induced by cysteine proteases, we confirmed that trypsin, a serine protease, does not activate MrgprC11³. Western blotting revealed PKC phosphorylation at serine 660 (Ser660) following treatment with cat S and papain (Fig. 2c). Quantification of the bands revealed an approximate 4.6 fold increase in pPKC associated with protease activation relative to controls (Supplementary Fig. 3).

We next assessed whether cysteine proteases activate endogenously expressed Mrgpr receptors on DRG neurons. Both cat S and papain treatment evoked calcium signals in DRGs from wt mice (Fig. 2d). Fewer DRGs neurons harvested from mice in which a cluster of *Mrgpr* genes, including MrgprC11, have been deleted (*Mrgpr cluster*^{-/-} mice), responded to cat S (Fig. 2d). The lack of response of these neurons to papain is likely due to receptor inactivation by papain under the conditions used. Because cat S is known to activate PAR2 when it is expressed in heterologous cell lines¹¹, we evaluated the effect of cat S on DRGs harvested from *PAR2*^{-/-} mice. Of note, calcium responses to cat S remained intact in the absence of PAR2 receptors (Fig. 2d). These data support a role for protease-induced MrgprC11 activation in DRGs, and importantly, identify cat S as a potential endogenous and relevant 'ligand' for this receptor. The average diameter of responsive neurons was 19.3 μm, comparable to that reported previously for Mrgpr-expressing itch neurons.

RNAi knockdown of MrgC11 and closely related MrgprA3 was performed in DRG neurons (Fig. 3). mRNA levels of both genes were significantly lower as confirmed by real time PCR

(Fig 3d). Knock down of MrgprC11 only abolished the calcium response to the MrgprC11 ligand cat S but not the MrgprA3 ligand chloroquine. In contrast, knock down of MrgprA3 only affected the response to chloroquine but not the response to cat S, showing effectiveness and specificity of RNAi. Note that transient knockdown of MrgprC11 totally abolished the cat S induced response while knockdown of MrgprA3 only reduced the response to chloroquine. This result is consistent with the stronger knockdown effect of MrgprC11. The observation that transient knockdown eliminates the calcium response to cat S suggests that the remaining calcium response in Mrgpr cluster knockout mice may be due to an otherwise unspecified compensation mechanism in the permanent knockout. In summary, these data support a role for protease-induced MrgprC11 activation in DRGs, and importantly, identify cat S as a potential endogenous and relevant ‘ligand’ for this receptor.

Cathepsin S induces scratching via MrgprC11

Cat S has been shown previously to cleave and activate PAR2 *in vitro*¹¹. It has been assumed, but never demonstrated clearly, that PAR2 activation is the mechanism by which cat S evokes scratching in mice and itch in humans¹¹. However, in light of our *in vitro* findings that cat S-induced calcium signaling in DRGs requires MrgprC11 but not PAR2, we sought to determine the relative importance of these two receptors, if any, to cat S-induced scratching *in vivo*. We thus compared behavioral scratching responses to intradermal injection of cat S using the mouse cheek model in wt, *Mrgpr cluster*^{-/-} mice, and *PAR2*^{-/-} mice. Pain and itch can be readily distinguished using the cheek injection model¹⁵. We only observed itch associated hind paw scratching but not pain related fore paw wiping. Injection of cat S elicited robust scratching behavior in wt mice, but was markedly reduced in *Mrgpr cluster*^{-/-} mice (Fig. 4a). Perhaps surprisingly, scratching in *PAR2*^{-/-} mice was as robust as in wt littermates (Fig. 4b). These experiments underline the pivotal role of MrgprC11 in mediating cysteine protease-induced itch.

MrgprC11 N-terminal cleavage sites

We next sought to determine if cleavage of the extracellular N-terminal domain of MrgprC11 is necessary for protease-induced receptor activation, and if so, identify the relevant cleavage sites. Per the MEROPS database, preferred amino acids for cleavage by cat S and papain include leucine at P2 and glycine, serine and aspartic acid at P1. Using site-specific mutagenesis, we generated a series of single, double and triple substitution mutants near the MrgprC11 N-terminus (Table 1 and Supplementary Information Note 1). Calcium imaging of HeLa cells transfected with these mutant receptors revealed that leucine¹⁵ was a critical residue for cat S mediated cleavage and activation. Papain required both aspartic acid⁹ and leucine¹⁵ for receptor cleavage and activation (Table 1 and Supplementary Information Table 1). None of the other candidate residues including glycine¹⁹, serine^{6, 7, 30} and leucine²⁷ were required for receptor activation by either protease.

To determine the specific protease cleavage sites, a peptide corresponding to the 28 N-terminal residues of MrgprC11 was synthesized, MDPTISSHD⁹TESTPL¹⁵NETGHPNCTPILT. The aspartic and leucine residues required for papain and cat S activity are indicated. This peptide was incubated with cat S or papain and then subjected to MS/MS peptide sequence analysis, as described in Supplementary Table 1 and Note 1, as we have

done previously with cat S and PAR2¹⁶. Cat S cleavage occurred between N¹⁶ and E¹⁷ with L¹⁵ at the P2 position, MDPTISSHD⁹TESTPL¹⁵N↓ETGHPNCTPILT, consistent with the site-directed mutagenesis approach above. Substituting arginine for leucine¹⁵ completely eliminated the response to cat S (Table 1 and Fig. 5b). Papain preferred L¹⁵ at the P2 position and cleavage between N¹⁶ and E¹⁷ but no additional specificity was apparent, and cleavage otherwise occurred at multiple sites.

MrgprC11 is not activated by tethered or diffusible ligands

As conventional PARs are activated by tethered ligands generated following protease-mediated cleavage of their N-terminal domains, we sought to determine if such peptides could activate MrgprC11. We generated a series of eight peptides (Fig. 5a and Supplementary Table 2) ranging from 6 to 15 amino acids based on predicted cleavage sites near the MrgprC11 N-terminus. These included the tethered hexapeptide ETGHPN that begins at the cat S cleavage site and the diffusible peptide MDPTISSHDTESTPLN that begins at the N-terminus of MrgprC11 and ends at the cat S cleavage site. In contrast to PAR2 N-terminal peptides, synthetic MrgprC11 N-terminal peptides failed to elicit calcium responses in MrgprC11-expressing cells (Fig. 5b and Supplementary Figure). These data reveal that in contrast to the activation of PARs, Mrgpr activation does not occur via generation of either a tethered or diffusible ligand.

Proteases activate β 2AR and MC1R-MrgprC11 hybrid receptors

We have shown thus far that protease-mediated cleavage of MrgprC11 causes receptor activation without the formation of either a tethered or diffusible ligand. Another possible explanation of the ability of cysteine proteases to activate Mrgprs is that proteolysis of the extracellular domain results in a direct conformational change of the intracellular portion of the receptor that allows G-coupled signaling to occur. If this is the case, a mutant MrgprC11 in which the native N-terminus has been substituted with the N-terminus of an unrelated GPCR that can also be cleaved by cysteine proteases might be activated by proteolysis. To evaluate this possibility, we substituted the N-terminus of MrgprC11 with either that of the β 2-adrenergic receptor (β 2AR) or the melanocortin-1 receptor (MC1R). These receptors are class A GPCRs, like Mrgprs, but they couple primarily to Gs. We selected β 2AR and MC1R because of the deep knowledge surrounding their structure and function. Each of these receptors contains residues that can be cleaved by cysteine proteases. However, biogenic amines and melanocortins respectively, not proteases, are their conventional ligands. As predicted, both cat S and papain treatment of HeLa cells transfected with hybrid receptors, β 2AR-MrgprC11 or MC1R-MrgprC11 resulted in robust calcium signaling. As controls, protease treatment did not result in calcium mobilization in HeLa cells expressing native β 2AR or MC1R (Fig. 6). Taken together with the site specific mutagenesis results, these findings argue that cat S- or papain-mediated cleavage of specific N-terminal residues directly triggers conformational changes in the transmembrane and/or intracellular domains of the MrgprC11 receptor that lead to downstream signaling.

Effect of cysteine proteases on other Mrgprs

To determine if cysteine protease-mediated receptor activation was specific to MrgprC11, we examined whether cat S and papain were capable of triggering calcium mobilization in

HeLa cells transfected with other members of the Mrgpr family, including human MRGPRX1-4 as well as mouse MrgprA3, which mediates chloroquine-induced itch. We found that in addition to activating human PAR2 and mouse MrgprC11, cat S activated human MRGPRX2 (Table 2 and Supplementary Fig. 5). Cat S failed to activate other human MRGPRs and mouse MrgprA3 (Table 2). In contrast, papain activated human MRGPRX1, but had no effect on the other human MRGPRs (Table 2 and Supplementary Fig. 5). As expected, trypsin failed to activate these Mrgprs (Fig. 2a and Table 1). These results demonstrate that cysteine proteases activate only select Mrgprs, and that cat S in particular activates mouse and human Mrgprs that have been implicated in itch transmission.

Discussion

Endogenous and exogenous proteases have long been implicated in the pathogenesis of many inflammatory diseases, including skin diseases^{9, 10, 17, 18}. Our previous work showed that endogenous cat S and other proteases trigger histamine-independent itch⁹⁻¹¹. Transgenic mice in which cat S is overexpressed spontaneously develop an intensely pruritic, eczematous disorder resembling atopic dermatitis¹⁹. In addition, cat S levels are selectively upregulated in psoriatic keratinocytes¹⁸, a condition also associated with considerable itch²⁰⁻²². Intradermal injection of cat S elicits acute itch in human subjects as well as scratching in mice^{11, 19}. Until now, the exact mechanism by which cysteine proteases induce itch remained elusive and was presumed to require activation of the PAR2 receptor via generation of KVDGTS, a tethered ligand distinct from SLIGRL¹⁶. We demonstrate for the first time that the cysteine proteases cat S and papain directly activate MrgprC11 to evoke histamine-independent scratching behavior. The activation kinetics of MrgprC11 by papain were prolonged relative to that of cat S. The mechanism for this prolonged activation is not clear but may result from a balance of receptor activation/inactivation, calcium-induced release from intracellular stores, or perhaps endosomal receptor signaling associated with papain^{23, 24}.

Consistent with protease activation of MrgprC11, scratching responses elicited by the intradermal injection of cat S were significantly reduced in *Mrgpr cluster*^{-/-} mice, but remained intact in *PAR2*^{-/-} mice. *In vitro* correlates of these *in vivo* observations were demonstrated as the capacity of cat S to activate DRG neurons from *Mrgpr cluster*^{-/-} mice was markedly diminished while not significantly diminished in *PAR2*^{-/-} DRG neurons. RNAi knockdown of MrgprC11 specifically abolished the response of DRG neurons to cat S. In contrast, knockdown of MrgprA3, did not diminish the response of DRG neurons to cat S. It is not clear why the decrease in scratching responses in *Mrgpr cluster*^{-/-} mice, while significant, was not as substantial as the decrease in Ca⁺⁺ signals in DRG neurons from these mice. An explanation is that cat S activates PAR2 on keratinocytes, resulting in the release of thymic stromal lymphopoietin (TSLP), a skin-derived cytokine which has been shown to induce itch via neuronal receptors for this molecule²⁵. In addition, while PAR2 does not appear to have a direct role in cat S-evoked itch in wt mice, a non-native role may be unmasked in the absence of MrgprC11. Our data also identify the cysteine protease cat S as a functional endogenous ligand for Mrgprs, currently considered orphan receptors. Whether other endogenous cysteine proteases activate Mrgprs awaits future investigations.

Conventional protease-activated receptors (PARs) are GPCRs that are uniquely activated by proteolysis. In this scenario, proteases bind and specifically cleave residues in the N-terminal domain of the receptor to unmask a 'tethered' ligand that subsequently interacts with another portion of the receptor to trigger intracellular signaling. Similarly, PARs can be activated by synthetic hexapeptides that mimic the first 6 amino acids of the unmasked N-terminus. The data presented here are the first to demonstrate that GPCRs other than PARs can be activated by proteolysis, as cysteine proteases activate MrgprC11. Site-specific mutagenesis revealed that cat S requires L¹⁵ and papain requires D⁹ and L¹⁵ for cleavage while data from MS/MS demonstrated that cleavage occurs between residues N¹⁶ and E¹⁷. In contrast to PARs, tethered ligands do not appear to play a role in Mrgpr activation and synthetic Mrgpr N-terminal peptides have no apparent functional activity. These data highlight the possibility that cysteine proteases may exert effects on other 'non-PAR' GPCRs and further suggest that proteases are capable of modulating GPCRs by multiple mechanisms.

Classically, GPCRs are thought to become activated when ligands bind in a pocket formed by the transmembrane helices thereby triggering exposure of cytoplasmic domains required for coupling to heterotrimeric G protein subunits²⁶. PARs, on the other hand, become activated when proteolysis allows for tethered ligands to interact with residues in the second extracellular loop, subsequently resulting in conformational changes in the transmembrane helices^{16, 27}. While the exact mechanism by which proteolysis triggers activation of MrgprC11 remains unknown, we suggest that the N-terminal domain interacts with the extracellular loops of the receptor to lock it in an inactive state. Cleavage of the N-terminus by cysteine proteases may release this lock, shifting transmembrane and cytoplasmic domains as suggested with traditional PARs. Our observations that calcium signaling was evoked by cathepsin-induced proteolysis of the β 2AR and MC1R N-terminal exchange mutants are consistent with this hypothesis. The mechanism underlying this observation deserves further study.

It is interesting that although N-terminal MrgprC11 peptides did not activate Mrgpr signaling, SLIGRL, a PAR2 N-terminal peptide, is capable of inducing itch via activation of MrgprC11³, at least at micromolar concentrations. Whether this effect occurs naturally is not clear. The concept that N-terminal peptides released into the extracellular milieu following PAR cleavage may exert a biologic effect independent of PARs has been reported. PAR1 cleavage by thrombin generates an N-terminal peptide known as parstatin which is capable of inhibiting vascular endothelial cell growth factor and fibroblast growth factor induced angiogenesis *in vitro* and *in vivo*. It also plays a role in modulating platelet function^{28, 29}. Whether protease-mediated cross-signaling between PAR2 and MrgprC11 serves a relevant role in coupling itch and inflammation *in vivo* is not known.

Cysteine proteases, in particular cysteine cathepsins, are widely expressed in mammalian tissues and have been implicated in the pathophysiology of a diverse array of inflammatory, autoimmune and allergic diseases as well as in neuropathic pain³⁰⁻³⁴. Recent work in murine colitis models demonstrates that macrophage- and microglial cell-derived cat S induces colonic inflammation and pain by activating PAR2 on different cell types, linking increased paracellular permeability in colonocytes with nociceptive hyper-excitability and

neurogenic inflammation in primary spinal afferent neurons^{30, 35–37}. We suggest that cat S may similarly act as a key regulator linking itch and inflammation in the skin. Our work reveals a novel mechanism by which cat S accomplishes its diverse effects: activation of MrgprC11.

Increased cat S expression has been reported in several common inflammatory skin conditions, including atopic dermatitis, psoriasis and seborrheic dermatitis^{18, 19, 38}. Under these conditions, cat S may simultaneously contribute to itch and propagate inflammation via different but related mechanisms. First, as we demonstrated here, cat S induces itch directly by activating MrgprC11. Second, cat S-mediated activation of PAR2 may induce itch if PAR2 N-terminal peptides bind to MrgprC11 on primary sensory nerves. In addition, PAR2 activation in keratinocytes may trigger release of TSLP which in turn activates cutaneous sensory neurons that express transient receptor potential ankyrin channel A1 (TRPA1), leading to itch stimulation and neurogenic inflammation²⁵. Recognizing that proteases can recruit multiple distinct pathways to induce itch and inflammation may help drive the development of more effective therapeutic strategies to treat inflammatory diseases, shifting the focus from blocking individual downstream receptors to inhibiting protease-receptor complexes.

Methods

Reagents, peptides and antibodies

Recombinant cat S was generated as previously described^{11, 16} and diluted in 1× PBS, pH 7.4, 5 mM EDTA, 5 mM DTT and 5 mM cysteine chloride. Papain (Sigma-Aldrich) was diluted in 0.1 × PBS, 50 mM sodium acetate, pH 6.5, 5 mM EDTA, 5 mM DTT and 5 mM cysteine chloride. Crystalline papain is more active and has a broader cleavage range than recombinant cat S. Different incubation times or concentrations were thus used as indicated. N-terminal peptides derived from the sequence of MrgprC11 were obtained from GenScript and diluted in PBS. The 28 amino acid N-terminal peptide MDPTISSHDTSTPLNETGHPNCTPILT was made by Peptide 2.0 (Chantilly, VA). The cysteine protease inhibitor E-64 was obtained from Sigma-Aldrich. Similar results were obtained at either 5 or 10 μM of this compound. Anti-Gaussia luciferase, catalog # E8023S from New England Biolabs was used at a dilution of 1:1500. Anti-phospho-PKC (pan) (βII Ser660) catalog #9371 from Cell Signaling Technology was used at a dilution of 1:1,000. HRP-labeled donkey anti rabbit, catalog # NB660-894 and anti-mouse antibodies catalog # NB7544 were from Thermo Fisher and used at 1:2,000 and 1:5,000 respectively. MW markers were Bioreagents EZ-run prestained rec protein ladder, cat # 3603500 from Thermo Fisher. All other reagents were purchased from Invitrogen unless otherwise noted.

Mice

Wild type and PAR2 KO mice were obtained from Jackson Laboratories. *Mrgpr cluster*^{-/-} mice were generated by X.D. as previously described². The mouse studies were performed at Johns Hopkins and approved by the IACUC at that institution.

Cell culture

HeLa cells were obtained from the ATCC and maintained in DMEM supplemented with fetal bovine serum, L-glutamine, penicillin and streptomycin (Fisher Biochemicals).

Dissociated dorsal route ganglion (DRG) neurons were prepared from wt, *Mrgpr cluster*^{-/-}, *PAR2*^{-/-} and *Pirt-GCaMP3* mice as reported previously². DRGs were collected from all spinal levels of 4-week old mice, placed in cold medium and treated with enzyme solution at 37°C. Following trituration and centrifugation, cells were suspended, plated on glass cover slips coated with poly-D-lysine and laminin, incubated at 37°C and used within 48 hours.

Cloning of wild-type MrgprC11 and generation of mutants

The coding region of MrgprC11 was cloned by PCR from mouse genomic DNA using the forward and reverse primers: GCGCTCGAGAGCATGGATCCAACCATCTCATC and GCGAAGCTTTCAATATCTGCTTTCTGAAATCTC. C11 N-terminal mutants were made by site-specific mutagenesis procedures using the primer pairs listed in Supplementary Table 3 to change the listed residues to isoleucine or arginine at the P2 site. Leucine at P2 is the preferred site for cleaved by cathepsin S as in native MrgprC11, with isoleucine less so and arginine not at all.

Preparation of Gaussia luciferase-MrgprC11 fusion cDNAs

Gaussia luciferase cDNA was cloned, without its termination codon, into pcDNA3.1(-) as an Xba I-Xho I fragment. MrgprC11 cDNA was fused as an Xho I-Hind III unit at the 3'-terminus of the luciferase cDNA to obtain LucMrgprC11.

Preparation of MrgprC11 with β 2AR and MC1R amino termini

The MrgprC11 coding region without its N-terminus from amino acid 34 to its C-terminus was cloned as an EcoR I – Hind III cDNA into pcDNA3.1(-) to obtain the vector pMrgprC11NR. The N-termini of β 2AR and MC1R from amino acids 1–34 and 1–37 respectively were isolated as Xho I – EcoR I fragments by PCR, and cloned into pMrgprC11NR to generate the vectors pARC11 and pMC1RC11 for expression of the chimeric receptors β 2AR- MrgprC11 and MC1R-MrgprC11.

Calcium imaging

HeLa cells were grown to confluence, trypsinized and then transfected with the pcDNA vector carrying the *G.luciferase*-MrgprC11 fusion construct, MrgprC11 cDNA or salmon sperm DNA as a control using Lipofectamine 2000. Transfected cells were plated into 96-well glass bottom plates at 50,000 cells/well and maintained at 37°C in 5% humidified CO₂ for 3 hours after which time the medium was replaced. Twenty-four to 48 hours after transfection, cells were incubated for 60 minutes at room temperature with 2 μ M of Fura-2-acetoxymethyl ester (Fura-2) diluted in complete DMEM. Following Fura-2 loading, the medium was replaced with 90 μ l of HEPES-buffered saline (20 mM HEPES, 115 mM NaCl, 5.4 mM KCl, 2 mM CaCl₂, 0.8 mM MgCl₂, 13.8 mM glucose, pH 7.4) and cells were used

immediately for calcium imaging. A luciferase-receptor construct was used in all transfections to establish consistency of transfection efficiency.

Ratiometric calcium imaging was performed using a Zeiss Axiovert 200M microscope equipped with a flipping filter wheel and Axiovision software (version 4.6). Peptide and protease agonists, cat S or papain (10 μ l) were added 15 seconds after initiating image acquisition. Images were acquired at time 0 and every 5 seconds thereafter for at least 90 seconds. All images obtained during each acquisition period were analyzed. Each experiment was performed at least three times and ratiometric changes were measured in at least twenty cells per acquisition with responses of three representative cells depicted in figures in the Results or Supplementary Information.

Primary DRGs cultured from wt, *Mrgpr cluster*^{-/-} and *PAR2*^{-/-} mice were loaded with Fura-2 for 30 min at 37° C for ratiometric calcium imaging as described above following application of cat S and papain (5 μ M and 20 μ M respectively). For experiments incorporating RNA interference, *MrgprA3* and *MrgprC11* on-target siRNAs were purchased from Thermo Scientific. 0.175 nmol *MrgprA3* or *MrgprC11* siRNA were electroporated respectively into DRG neurons from *Pirt-GCaMP3* mice that had been generated previously^{2, 39}. Electroporation of dissociated DRG neurons with *Mrgpr*-expression constructs was carried out using Mouse Neuron Nucleofector Kit (Amaxa Biosystems) following the manufacturer's instructions. Electroporated neurons were plated and cultured as described above and used within 72 hours. Green fluorescence from genetically encoded calcium GCaMP3 was detected via single photon Ca²⁺ imaging with a 700 Zeiss confocal microscope, using the 488 nm line of a solid state laser for excitation of *Pirt-GCaMP3* and a 488 nm laser main dichroic beam splitter (MBS) and a 505–555 nm variable secondary dichroic mirror (VSD) to detect the emission of green fluorescence.

Real time quantitative PCR

Total RNA was extracted from cultured DRGs three days after siRNA electroporation by using an Rneasy micro kit (Qiagen). Purified RNA was quantified on a Nanodrop 2000 UV spectrophotometer (Thermo Scientific) at 260 nm and assessed for purity by using the 260/280 nm ratio. DNA was reverse transcribed with the Superscript First Strand Synthesis System (Invitrogen). PCR amplifications were carried out with a Step One Plus real time PCR system (Applied Biosystems). PCR conditions were 95°C for 3 minutes and 50 cycles of 95°C for 30 seconds and 60°C for 60 seconds. Primers as listed below: *MrgprC11*-F AGCATCCACAACCCAGGAAG; *MrgprC11*-R TGGAGTGCAGTTGGGATGAC; *MrgprA3*-F ACACAAGCCAGCAAGCTACA; *MrgprA3*-R ACTTCCAGGGATGGTTTCGT; *Actin*-F CGTCGACAACGGCTCCGGCATG; *Actin*-R CCACCATCACACCCTGGTGCCTAGG

All primers were intron spanning to avoid genomic DNA contamination. Melting curve analysis was applied to all final PCR products after the cycling protocol. Samples were run in triplicate, and threshold cycle (Ct) values from each reaction were averaged. Relative mRNA level of *MrgprA3* and *MrgprC11* were calculated from threshold cycles and normalized to actin level. Experiments were carried out three times with samples from different animals and the Student's t test used to determine significance.

Concentration-effect measurements for cat S and papain

HeLa cells transfected with MrgprC11 cDNA were analyzed using ratiometric imaging as described above with cat S and papain at concentrations from 1 nM – 10 μ M. Each of the concentration-dependent readings was performed in triplicate. Maximum intensities at each of the dilutions were calculated and plotted against concentration using GraphPad Prism software. Error bars represent SEM within an experiment although these experiments were performed multiple times with similar results.

Luciferase assay

MrgprC11 plasmid DNA (10 μ g) or salmon sperm as control were transfected into 2×10^6 HeLa cells as described above and plated into 10 cm dishes. Forty-eight hours after transfection, the cells were washed with PBS, scraped and pelleted. Cells were suspended in a volume of 200 μ l PBS and 100 μ l were incubated with cat S (2 μ M) or papain (0.02 μ M) in the presence or absence of the irreversible cysteine protease inhibitor E-64 for 10 minutes at room temperature. Control cells were not treated with protease. Protease activity was quenched by adding 300 μ l of complete DMEM, after which the cells were centrifuged and supernatants (50 μ l) were assayed in triplicate for luminescence according to the instructions of the manufacturer (New England Biolabs). These experiments were performed multiple times with protease activity being quenched at many different time points so as to catch luminescence associated with papain as this protease has the capacity to digest luciferase.

Western blot analysis for luciferase

HeLa cells transfected with the *G.luciferase*-MrgprC11 fusion construct were treated with cat S (2 μ M) or papain (0.02 μ M) for 10 minutes. Cells were pelleted and the supernatant was added directly to loading buffer to quench enzymatic activity, run on NuPAGE Novex Bis-Tris mini gels and transferred to nitrocellulose membranes. Membranes were probed with a primary rabbit anti-*G. luciferase* antibody followed by HRP-labeled donkey anti-rabbit antibody for reaction with the ECL-substrate to identify protein bands. The results presented are representative of one of four experiments.

Western blot analysis for p-PKC (Ser660)

HeLa cells were transfected with MrgprC11 plasmid DNA as described above and plated onto three 10 cm dishes. Non-transfected HeLa cells were also plated into three other 10 cm dishes. Forty-eight hours after transfection, cells were washed with PBS and then treated with papain or cat S at 0.02 μ M and 2 μ M respectively for 10 minutes. A subset of HeLa cells that were not transfected was treated with papain, cat S or PBS alone as controls. Cells were harvested by scraping, pelleted and lysed by repetitive freeze-thaw cycles. Cell lysates were centrifuged at 4° C for 15 minutes. Supernatants were collected and protein concentrations were determined by Bradford assay. Equal amounts of cell lysates were loaded onto NuPAGE Novex Bis-Tris mini gels, electrophoresed and transferred to nitrocellulose membranes. Membranes were probed with rabbit anti-phospho-PKC (β II Ser660) followed by incubation with HRP-labeled donkey anti-rabbit antibody for reaction with the ECL-substrate to identify protein bands on the membrane. The blot was re-probed with mouse anti-actin antibody to identify the control actin band (42 kDa). HRP-labeled

anti-mouse antibody was used as a secondary antibody for the ECL substrate. This experiment was repeated three times and error bars represent \pm SEM between the individual bands between three separate experiments with relative intensities quantitated using ImageJ.

Behavioral studies

All mice used for behavioral studies were 2- to 3-month-old males (20 to 30 g) and were backcrossed to C57BL/6 mice for at least 10 generations. Mice were habituated for 30 minutes/day for 3 days prior and then at least 15 minutes on the day of study. Intradermal injections of 10 μ l cat S 80 μ M were delivered to the cheek¹⁵. Scratching behavior was observed for 30 minutes. A scratching bout was defined as continuous scratching movements with hind paws directed at the site of injection. Scratching behavior was quantified by recording the number of scratching bouts at 5-minute intervals over a 30-minute observation period. Experimenters were blind to genotype. Data are presented as mean \pm SEM. n represents the number of mice analyzed or times of experiments performed. The distribution of the variables in each experimental group was approximately normal. Statistical comparisons were conducted by two-tailed, unpaired Student's t test. Differences were considered to be statistically significant for $P < 0.05$. Representative data are from experiments that were replicated biologically at least three times with similar results.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institutes of Neurological Disease and Stroke of the National Institutes of Health under Award Numbers R01AR05744 and R21AR067399 to EAL and R01NS054791 to XD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. XD is an Early Career Scientist of the Howard Hughes Medical Institute. Support was also provided by a grant from LEO Pharma to EAL. SBE is the recipient of a Career Development Award from the Dermatology Foundation and received support from the Women's Dermatologic Society. EA is the recipient of a grant from the National Eczema Association.

References

1. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. *Cell*. 2001; 106:619–632. [PubMed: 11551509]
2. Liu Q, et al. Sensory neuron-specific GPCR Mrgpr8 is itch receptors mediating chloroquine-induced pruritus. *Cell*. 2009; 139:1353–1365. [PubMed: 20004959]
3. Liu Q, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. *Science signaling*. 2011; 4:ra45. [PubMed: 21775281]
4. Wilson SR, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. *Nature neuroscience*. 2011; 14:595–602. [PubMed: 21460831]
5. Sikand P, Dong X, LaMotte RH. BAM8-22 peptide produces itch and nociceptive sensations in humans independent of histamine release. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2011; 31:7563–7567. [PubMed: 21593341]
6. Lembo PM, et al. Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. *Nature neuroscience*. 2002; 5:201–209. [PubMed: 11850634]

7. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. *British journal of pharmacology*. 2008; 153(Suppl 1):S263–S282. [PubMed: 18059329]
8. Liu Q, et al. Mechanisms of itch evoked by beta-alanine. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2012; 32:14532–14537. [PubMed: 23077038]
9. Reddy VB, Iuga AO, Shimada SG, LaMotte RH, Lerner EA. Cowhage-evoked itch is mediated by a novel cysteine protease: a ligand of protease-activated receptors. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2008; 28:4331–4335. [PubMed: 18434511]
10. Reddy VB, Lerner EA. Plant cysteine proteases that evoke itch activate protease-activated receptors. *The British journal of dermatology*. 2010; 163:532–535. [PubMed: 20491769]
11. Reddy VB, Shimada SG, Sikand P, Lamotte RH, Lerner EA. Cathepsin S elicits itch and signals via protease-activated receptors. *The Journal of investigative dermatology*. 2010; 130:1468–1470. [PubMed: 20072136]
12. Liu Q, et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. *Science signaling*. 2011; 4:ra45. [PubMed: 21775281]
13. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. *Nucleic acids research*. 2012; 40:D343–D350. [PubMed: 22086950]
14. Wilson SR, et al. TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch. *Nature neuroscience*. 2011; 14:595–602. [PubMed: 21460831]
15. Shimada SG, LaMotte RH. Behavioral differentiation between itch and pain in mouse. *Pain*. 2008; 139:681–687. [PubMed: 18789837]
16. Elmariah SB, Reddy VB, Lerner EA. Cathepsin S signals via PAR2 and generates a novel tethered ligand receptor agonist. *PloS one*. 2014; 9:e99702. [PubMed: 24964046]
17. Deschamps K, et al. Genetic and pharmacological evaluation of cathepsin s in a mouse model of asthma. *American journal of respiratory cell and molecular biology*. 2011; 45:81–87. [PubMed: 20855652]
18. Schonefuss A, et al. Upregulation of cathepsin S in psoriatic keratinocytes. *Experimental dermatology*. 2010; 19:e80–e88. [PubMed: 19849712]
19. Kim N, et al. Overexpression of cathepsin S induces chronic atopic dermatitis in mice. *The Journal of investigative dermatology*. 2012; 132:1169–1176. [PubMed: 22170489]
20. Prignano F, Ricceri F, Pescitelli L, Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. *Clinical, cosmetic and investigational dermatology*. 2009; 2:9–13.
21. Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. *Health and quality of life outcomes*. 2009; 7:62. [PubMed: 19580674]
22. Gupta MA, et al. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. *Archives of dermatology*. 1988; 124:1052–1057. [PubMed: 3389849]
23. Vilardaga JP, Jean-Alphonse FG, Gardella TJ. Endosomal generation of cAMP in GPCR signaling. *Nature chemical biology*. 2014; 10:700–706. [PubMed: 25271346]
24. Tsvetanova NG, Irannejad R, von Zastrow M. G Protein-coupled Receptor (GPCR) Signaling via Heterotrimeric G Proteins from Endosomes. *The Journal of biological chemistry*. 2015; 290:6689–6696. [PubMed: 25605726]
25. Wilson SR, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. *Cell*. 2013; 155:285–295. [PubMed: 24094650]
26. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. *The Journal of biological chemistry*. 1998; 273:17299–17302. [PubMed: 9651309]
27. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell*. 1991; 64:1057–1068. [PubMed: 1672265]
28. Zania P, et al. Parstatin, the cleaved peptide on proteinase-activated receptor 1 activation, is a potent inhibitor of angiogenesis. *The Journal of pharmacology and experimental therapeutics*. 2009; 328:378–389. [PubMed: 18988770]

29. Furman MI, et al. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. *Thrombosis and haemostasis*. 2000; 84:897–903. [PubMed: 11127874]
30. Cattaruzza F, et al. Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. *Gastroenterology*. 2011; 141:1864–1874. e1861–e1863. [PubMed: 21802389]
31. Inaoka T, et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. *Biochemical and biophysical research communications*. 1995; 206:89–96. [PubMed: 7818555]
32. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. *Nature reviews. Cancer*. 2006; 6:764–775. [PubMed: 16990854]
33. Clark AK, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. *Proceedings of the National Academy of Sciences of the United States of America*. 2007; 104:10655–10660. [PubMed: 17551020]
34. Gupta S, Singh RK, Dastidar S, Ray A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. *Expert opinion on therapeutic targets*. 2008; 12:291–299. [PubMed: 18269339]
35. Steinhoff M, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. *Nature medicine*. 2000; 6:151–158.
36. Jacob C, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. *The Journal of biological chemistry*. 2005; 280:31936–31948. [PubMed: 16027150]
37. Zhao P, et al. Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. *The Journal of biological chemistry*. 2014
38. Viode C, et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. *Experimental dermatology*. 2014; 23:274–275. [PubMed: 24690038]
39. Kim YS, et al. Central terminal sensitization of TRPV1 by descending serotonergic facilitation modulates chronic pain. *Neuron*. 2014; 81:873–887. [PubMed: 24462040]




Figure 1. Cysteine proteases cleave near the N-terminus of MrgprC11

a) Luminescence was measured after treating LucMrgprC11-transfected HeLa cells with cat S (2 μ M) and papain (2 μ M) in the presence or absence of E-64 (5 μ M). Baseline luminescence has been subtracted. The data are presented as mean \pm SEM. **, $P < 0.001$, *** $P < 0.0005$; ; two-tailed unpaired t-test from a representative experiment that was performed three times. **b)** Western blot of LucMrgprC11 N-terminus cleavage products following treatment of transfected HeLa cells with control buffer without proteases (lane 1), papain, 0.02 μ M (lane 2) and cat S, 2 μ M (lane 3). The lesser amount of luminescence from papain as compared to cat S in 1a is likely a result of higher enzyme activity and a broader range of cleavage sites for papain. Similarly, for 1b, a lesser concentration of papain as compared to cat S was used in order for incubation times to be the same for detection of luciferase. See Methods and Discussion for additional comments. The LucMrgprC11 construct was functionally active (Supplementary Fig. 1).




Figure 2. Cysteine proteases activate MrgprC11 in heterologous cells and DRG neurons and induce PKC phosphorylation

a) Single-cell calcium imaging in HeLa cells transfected with MrgprC11 cDNA following treatment with cat S (2 μ M, solid line), papain (2 μ M, dashed line), cat S + E-64 (10 μ M; dotted line) papain+E-64 (10 μ M; dash-dotted line) and trypsin (10 nM) dash-double-dotted line. The concentration of trypsin is typical of that used in studies of PARs. Higher concentrations of trypsin, including those in the μ M range, did not activate MrgprC11. Additional calcium responses are detailed in Supplementary Fig. 2. b) Concentration-effect curves for protease agonists cat S (squares) and papain (circles) on MrgprC11. Error bars represent \pm SEM from three sets of experiments. c, Phosphorylation of serine 660 as a measure of second messenger is revealed by Western blot. HeLa cells were transfected with MrgprC11 (lanes 1–3) or non-transfected HeLa cells (lanes 4–6) were treated with buffer alone (lanes 1 and 4), cat S (lanes 2 and 5) or papain (lanes 3 and 6). Band quantification and full scans of the blots are provided in Supplementary Fig. 3. d) The percentage of DRG neurons activated by cat S (5 μ M) was significantly reduced in *Mrgpr cluster knockout* mice

as compared with wt DRG neurons (n=3, p<0.001). The percentage of DRG neurons activated by papain (20 μ M) was reduced to zero in *Mrgpr cluster knockout* mice as compared with wt mice (n=3, ***, P<0.001; two-tailed unpaired t-test.). The percentage of DRG neurons activated by cat S (5 μ M) is not significantly different between wt and *PAR2^{-/-}* mice (n=3, p=0.74). (e) Representative calcium traces of cat S (5 μ M) in DRG neurons from wt, *Mrgpr cluster^{-/-}* and *PAR2^{-/-}* mice. Each trace represents responses from a single neuron. Arrows indicate application of cat S.




Figure 3. Acute knockdown of MrgprC11 abolishes DRG response to cathepsin S
 a) MrgprA3 knock down DRG neurons responded normally to cat S (5 μ M) while MrgprC11 knock down DRG neurons showed no response (n=4, p<0.05). In contrast, chloroquine (CQ) (2 mM) induces calcium responses in approximately 4% of MrgprC11 knockdown DRGs while knockdown of MrgprA3 markedly reduced the response to CQ (n=4, p<0.05). b) Representative calcium traces from MrgprA3 knockdown DRG neurons in response to cat S and chloroquine. c) Representative calcium traces from MrgprC11 knockdown DRG neurons in response to cat S and chloroquine. Each trace represents

responses from a single neuron. Arrows indicate application of cat S. d. Relative mRNA level of MrgprA3 and MrgprC11 in the respective knockdown DRGs as determined by real-time PCR. The data are presented as mean \pm SEM. *, P<0.05, **, P<0.01; ***, P<0.001; two-tailed unpaired t-test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Cathepsin S induced scratching is reduced in *Mrgpr cluster*^{-/-} mice
a) Scratching behavior of wt and *Mrgpr cluster*^{-/-} mice in response to cat S, n=11, p = 0.04 and compared to baseline saline vehicle alone (n=9). **b)** Scratching behavior of wt and *PAR2*^{-/-} mice in response to cat S was not significantly different, n=7, p value 0.32. The data are presented as mean \pm SEM. *, P<0.05; two-tailed unpaired t-test.





Figure 5. N-terminal peptides do not activate MrgprC11 and cat S requires L¹⁵ for activity. a) A series of eight MrgprC11 N-terminal peptides was generated based on possible protease cleavage sites. b) Calcium imaging of HeLa cells transfected with MrgprC11 following treatment with a representative MrgprC11 N-terminal peptide, C11-1 100 μ M, the hexapeptide tethered ligand ETGHPN at the cat S cleavage site. c) Cat S does not activate the MrgprC11 in which L¹⁵ has been changed to R. Note that SLIGRL activates the native and mutant receptors.




Figure 6. Cathepsin S and papain activate MrgprC11 downstream signaling in N-terminus exchange receptors

a) Cat S and papain activate β_2 AR-MrgprC11 but not the wild-type AR as determined by calcium imaging. b) Cat S and papain activate MC1R-MrgprC11 but not wild-type MC1R as determined by calcium imaging. See Supplementary Fig. 4 for additional detail.

Table 1

Responses of wild-type MrgprC11 or MrgprC11 N-terminal mutants following treatment with cat S, papain or SLIGRL as determined by calcium imaging. '+' indicates that the indicated receptor was activated. Representative calcium imaging data is presented in Supplementary Fig. 2. The indicated amino acids were each mutated to isoleucine except for mutant MrgprC11-9 in which L¹⁵ was changed to R. Note that SLIGRL activated all of the receptors.

MrgprC11 N-terminus: M ¹ DP TIS SHD TES TPL NET GHP NCT PIL TLS FLV ³³			
MrgprC11 wt and mutant receptors	Cat S, 2 μM	Papain, 2 μM	SLIGRL, 10 μM
C11 wt	+	+	+
C11-1 (L ¹⁵ I)	-	+	+
C11-2 (G ¹⁹ I)	+	+	+
C11-3 (L ¹⁵ I, G ¹⁹ I)	-	+	+
C11-4 (L ¹⁵ I, G ¹⁹ I, L ²⁷ I)	-	+	+
C11-5 (S ³⁰ I)	+	+	+
C11-6 (D ⁹ I)	+	+	+
C11-7 (D ⁹ I, L ¹⁵ I)	-	-	+
C11-8 (S ⁶ I, S ⁷ I)	+	+	+
C11-9 (L ¹⁵ R)	-	+	+

Table 2

Responses of PAR2 and Mrgprs following treatment with cat S, papain and trypsin as determined by calcium imaging. '+' indicates that the indicated receptor was activated. Representative calcium imaging data is presented in Supplementary Fig. 5.

GPCR	Cat S, 2 μ M	Papain, 2 μ M	Trypsin, 10 nM
hPAR2	+	+	+
hMRGPRX1	-	+	-
hMRGPRX2	+	-	-
hMRGPRX3	-	-	-
hMRGPRX4	-	-	-
mMrgprC11	+	+	-
mMrgprA3	-	-	-

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript